HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

1,200

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

April 1, 2026

Conditions

COVID-19

Interventions

DRUG

HH-120 Nasal Spray

HH-120 nasal spray 8 times per day for 7 consecutive days

DRUG

Placebo

Placebo 8 times per day for 7 consecutive days

Trial Locations (2)

Beijing Ditan Hospital, Capital Medical University, Beijing

Huashan Hospital of Fudan University, Shanghai